Phase

EQS-News: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Retrieved on: 
星期三, 四月 10, 2024
Q&A, Associate, Oncology, Internet, Doctor of Philosophy, Spacecraft, MD, AACR, HPHA, Phase, ADC, BST, Hematology, ATAC, Annual general meeting

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.

Key Points: 
  • Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.
  • The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline.
  • Attendees will have the opportunity to participate in a live Q&A session at the end of the presentation or submit questions in advance of the event.
  • For further information on the R&D webinar, or to register your interest, please contact Optimum Strategic Communications at [email protected] or register using the link below:

Clearmind Medicine CEO Issues Letter to Shareholders

Retrieved on: 
星期二, 四月 9, 2024
Data monitoring committee, Depression, Obesity, Mevalonate pathway, Psychiatry, Dyskinesia, Addiction, Safety, Binge drinking, Data, DSM-IV codes, Research, MEAI, Clinical trial, Johns Hopkins University, Phase, Patent, Therapy, Ministry, FDA, Impulsivity, CTS, IRB, Pharmaceutical industry

Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.

Key Points: 
  • Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.
  • CMND-100, a pioneering MEAI-based (5-methoxy-2-aminoindane) formula, has exhibited encouraging results in pre-clinical studies.
  • Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations—a common concern with existing treatments.
  • The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Retrieved on: 
星期一, 四月 8, 2024
Ovarian cancer, Cetuximab, CRDF, RAS, Patient, Bev, PLK1, Abstract, AACR, Bevacizumab, Cancer, Phase, Data, SCLC, Pharmaceutical industry

In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.

Key Points: 
  • In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.
  • In addition, we are particularly encouraged by our RAS-mutated mCRC preclinical data highlighting onvansertib’s ability to inhibit activation of the hypoxia pathway via the regulation of HIF1α.
  • All the abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following the presentation, the posters will be posted to the “ Scientific Presentations ” section of the Cardiff Oncology website.

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
星期三, 四月 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
星期三, 四月 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
星期二, 四月 2, 2024
Hospital, TMX Group, Teaching hospital, Phase, OTCQB, Liver

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The three new hospitals joining the Phase II study are Istanbul University-Cerrahpaşa, Sütçü İmam University Hospital in the city of Kahramanmaraş, and the Gazi University Hospital in Ankara, the capital of Turkey.
  • The trial now has a total of seven clinical sites across Turkey and Canada.

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 四月 2, 2024
Research, Failure, Plasma, KPMG, TDP43, Disease, PD, CSF, Yale University, Patient, Inflammation, Biomarker, CMC, Equity, TAR, Human, European, Drug development, ATM, Safety, Phase, Therapy, Vaccine, Treasury, Syneos Health, Axonal transport, Pharmaceutical industry

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  • For the quarter ended December 31, 2023, Annovis reported a net loss of $22.2 million, compared to a net loss of $7.7 million for the same period in 2022.
  • For the full year ended 2023, Annovis reported a net loss of $56.2 million, compared to a net loss of $25.3 million in 2022.
  • Other income (expense) for the quarter ended December 31, 2023 was ($11.2) million, compared to $0.2 million for the same period in 2022.

Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States

Retrieved on: 
星期三, 三月 27, 2024
FACC, Obesity, Gastroparesis, Metoclopramide, Diabetes, Patient, Volunteering, MD, IND, Nausea, European, Investigational New Drug, Safety, Pharmacokinetics, Phase, Conditional sentence, Vomiting, FDA, Bloating, Pharmaceutical industry

Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

Key Points: 
  • Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.
  • Renexxion and Dr. Falk Pharma will now expand patient enrollment for the ongoing global multi-center 320 patient placebo-controlled Phase 2b MOVE-IT study in gastroparesis to clinical sites in the United States (ClinicalTrials.gov ID: NCT05621811).
  • Furthermore, naronapride has already demonstrated dose-dependent accelerated gastric emptying in a GI transit study of healthy human volunteers.
  • We are aligned in our belief in the transformative power of naronapride to revolutionize treatment for gastroparesis patients and its ability to reshape the gastroparesis treatment landscape.”

Inventiva reports its 2023 full-year results

Retrieved on: 
星期三, 三月 27, 2024
DSM-IV codes, NMPA, Acceleration, Partnership, Patient, Income tax, G&A, BofA Securities, MASH, Equity, SUSAR, IND, Marketing, Bank statement, IRB, Clinical trial, Investigational New Drug, European Investment Bank, Fatty liver disease, Type 2 diabetes, T2D, Euronext Paris, EIB, Phase, Optimism, NAFLD, Sino Biopharmaceutical Limited, Pharmaceutical industry

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.

Key Points: 
  • Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.
  • R&D expenses for the fiscal year ended December 31, 2023, amounted to (€110.0) million compared to (€60.5) million in 2022.
  • Net financial income was (€5.1) million for the fiscal year ended December 31, 2023, compared to €2.8 million in 2022.
  • Income tax amounted to (€0.6) million for the 2023 fiscal year, compared to €0 million for 2022.

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax

Retrieved on: 
星期一, 四月 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Azacitidine, VTX, Phase, Wake Forest University, Patient, Trial of the century, Survivor, Acute myeloid leukemia, Cancer, AML, Pharmaceutical industry

Accordingly, we can start the Phase I/II combo-study very soon.

Key Points: 
  • Accordingly, we can start the Phase I/II combo-study very soon.
  • The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML.
  • This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML.
  • Please take notice of our own innovative approach for miserable cancer patients and contact with us.